Publications by authors named "S Morishima"
Article Synopsis
- Researchers are testing valemetostat, an EZH2 and EZH1 inhibitor, for safety and effectiveness in patients with relapsed or refractory non-Hodgkin lymphoma, due to limited treatment options and poor outcomes.
- The study involved 90 participants from 19 hospitals across Japan and the USA, who received varying doses of valemetostat in a phase 1 clinical trial to find the right dosage and assess its anti-tumor effects.
- Initial findings will help determine the most effective dosages and provide insights into the drug's safety profile, with a majority of patients having peripheral T-cell lymphoma.
This study retrospectively compared outcomes of various allogeneic haematopoietic cell transplantation (allo-HCT) platforms in patients with adult T-cell leukaemia/lymphoma. Platforms included human leukocyte antigen (HLA)-haploidentical-related donors using post-transplant cyclophosphamide (PTCY), HLA-matched related donors (MRD), HLA-matched unrelated donors (MUD) and cord blood transplantation (CBT). Patients who underwent their first allo-HCT between 2016 and 2021 were included.
View Article and Find Full Text PDFChildhood is considered crucial in the establishment of future oral microbiota. However, the precise period of oral microbiota development remains unclear. This study aimed to identify the progression of oral microbiota formation in children.
View Article and Find Full Text PDFArticle Synopsis
- Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can lead to long-lasting remission in adult T-cell leukemia/lymphoma (ATL) patients, but there's a lack of research on post-transplant outcomes for younger patients (≤49 years).
- A study found that patients aged <40 years had a significantly better overall survival rate (61.8%) compared to those aged 40-49 years (43.1%), indicating younger patients fare better post-transplant.
- Moreover, while there were no major differences in survival outcomes between different conditioning regimens, the reduced-intensity conditioning (RIC) regimen resulted in lower non-relapse mortality compared to the myeloablative conditioning (MAC) regimen